Loading…
Can-Fite BioPharma Ltd.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in CANF.
▼ -99.3% over 5Y.
today you would have $6.51▼ -99.3%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 8 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $4.00 | $32.60 | $44.00 | $122.00 | $258.00 | $356.00 | $660.00 | $3,780.00 | |
| P/S | 1081.9x | 25.9x | 48.1x | 4026.4x | 6143.3x | 12336.6x | 1081.9x | 195.9x | — |
| P/B | 163.0x | 1.9x | 6.0x | 479.2x | 1112.7x |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| INMInMed Pharmaceuticals Inc. | $1.38 | — | 0.7x | — | -112.65% | $7.37M |
| CURXCuranex Pharmaceuticals Inc | $4.56 | — | 1.4x | — | -411.08% | $7.15M |
| BOLTBolt Biotherapeutics, Inc. | $3.71 | — | 0.6x | — | -111.65% | $7.15M |
| INBSIntelligent Bio Solutions Inc | $2.36 |
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, It offers cannabinoids for treatment of conditions associated with elevated expression of the A3 adenosine receptors. Further, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.
Company description provided by Yahoo Finance.
| 731.7x |
| 135.9x |
| 163.0x |
| — |
| EPS | -$5.97 | -$10.86 | -$17.92 | -$0.20 | -$0.60 | -$0.80 | -$28.00 | -$34.00 |
| Profit margin | -1212.53% | -2426.67% | -1169.14% | -1027.46% | -1255.93% | -1478.90% | -1892.92% | -621.31% | -172.02% |
| ROE | -196.85% | -175.75% | -144.96% | -122.28% | -227.48% | -87.71% | -237.78% | -516.99% | -217.94% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 1.2x |
| — |
| -307.69% |
| $7.14M |
| NVNOenVVeno Medical Corp | $10.75 | — | 0.4x | — | -58.53% | $7.47M |
| CELZCreative Medical Technology Holdings Inc | $1.14 | — | 0.9x | — | -77.88% | $7.52M |